Amgen

PLEXIUM ANNOUNCES APPOINTMENT OF SUZANNE ZOUMARAS AS EXECUTIVE VICE PRESIDENT, HEAD OF HUMAN RESOURCES

Retrieved on: 
Thursday, September 29, 2022

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Suzanne Zoumaras as Executive Vice President, Head of Human Resources.

Key Points: 
  • SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Suzanne Zoumaras as Executive Vice President, Head of Human Resources.
  • "Suzanne is a business-minded human capital leader, advisor and educator who understands the importance and impact that the right people have on building a successful company.
  • Prior to joining Plexium, Ms. Zoumaras was a Co-Founder and Managing Partner of Human Capital Resource Partners, a human capital and advisory services consulting firm.
  • Before that, she served as Executive Vice President & Chief Human Capital Officer at Arena Pharmaceuticals, Executive Vice President and Chief Human Resource Officer at Teradata, and as Senior Vice President of Global Human Resources at Atmel Corporation (acquired by Microchip).

Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer

Retrieved on: 
Thursday, September 29, 2022

Mr. Caldemeyer added, “Recludix’s drug discovery platform has been prolific. With several programs being advanced for oncology and inflammatory diseases, there are many opportunities for the company to transform treatment paradigms for these patients. I am delighted to join the Recludix team.”   About RecludixRecludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company was founded by members of Blueprint Medicines’ founding scientific team and its management team includes industry veterans with a track record of success in the discovery, development and commercialization of multiple oncology drugs. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced programs are focused on Signal Transducer and Activator of Transcription (STAT) proteins -- STAT3 and STAT6 -- where abnormal activation is found in numerous cancer types, such as multiple leukemias and lymphomas, as well as inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis, inflammatory bowel disease, and others. The company is advancing three other programs to undisclosed targets that also play a significant role in both cancer and autoimmune diseases. For more information, please visit the company’s website at https://recludixpharma.com.

Key Points: 
  • SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Matthew Caldemeyer as chief business officer.
  • We are excited to welcome Matt to our executive leadership team, said Nancy Whiting, Pharm.D., chief executive officer of Recludix.
  • He previously served as head of business development at Ambrx and as director of corporate strategy and business development at Array BioPharma.
  • From 2004 to 2011, Mr. Caldemeyer was at Eli Lilly and Company where he held positions in business development, finance and manufacturing.

KRAS Kickers Give Cancer the Boot!

Retrieved on: 
Wednesday, September 28, 2022

CHARLOTTE, N.C., Sept. 28, 2022 /PRNewswire/ -- Cancer patient advocates, doctors, researchers, and pharmaceutical industry partners are joining forces during KRAS Kickers Connect conference Sept. 30-Oct. 1 in Charlotte. The in-person and virtual hybrid event features world renowned scientists and patient advocate leaders. KRAS Kickers Connect will be held Friday and Saturday at the Hyatt Centric Charlotte SouthPark, 3100 Apex Dr., Charlotte.

Key Points: 
  • CHARLOTTE, N.C., Sept. 28, 2022 /PRNewswire/ -- Cancer patient advocates, doctors, researchers, and pharmaceutical industry partners are joining forces during KRAS Kickers Connect conference Sept. 30-Oct. 1 in Charlotte.
  • KRAS Kickers Connect will be held Friday and Saturday at the Hyatt Centric Charlotte SouthPark, 3100 Apex Dr., Charlotte.
  • "For decades, KRAS-driven cancers were considered 'undruggable,'" says Terri Conneran, KRAS Kickers Founder and Charlotte lung cancer patient.
  • Conneran, who has been battling lung cancer since 2017, founded KRAS Kickers to create a network for patients and families in search of KRAS information and support.

RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

Retrieved on: 
Wednesday, September 28, 2022

It is a pleasure to welcome both Jennifer and Adnan to the RAPT leadership team at this exciting time of growth for the Company, said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.

Key Points: 
  • It is a pleasure to welcome both Jennifer and Adnan to the RAPT leadership team at this exciting time of growth for the Company, said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.
  • Prior to Kronos Bio, she was Head of Global Regulatory Science at Acerta Pharma, a member of the AstraZeneca Group.
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.
  • RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively.

DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO

Retrieved on: 
Tuesday, September 27, 2022

The company simultaneously announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology.

Key Points: 
  • The company simultaneously announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology.
  • Mr. Grmusa, Dr. Quva and Dr. Francisco-Anderson join experienced industry leader John McCabe who serves as Chief Financial Officer and Chief Operating Officer.
  • I am thrilled to join DEM Bio and to work alongside this world-class team of leaders in the emerging and highly promising field of innate immune system checkpoint inhibitors, said Mr. Grmusa.
  • Mr. Grmusa brings 20 years of industry experience in business development, pharmaceutical portfolio management, R&D finance and financial planning and analysis.

PM360 Magazine Announces Winners of 2022 Trailblazer Awards

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries. In total, 72 winners were named across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022.
  • The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries.
  • Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry.
  • PM360 will publish profiles of this year's Trailblazer winners in its October issue and on its website.

Janux Therapeutics Appoints Winston Kung to Board of Directors

Retrieved on: 
Thursday, September 22, 2022

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Winston Kung to the Companys Board of Directors.

Key Points: 
  • Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Winston Kung to the Companys Board of Directors.
  • Janux also announced that Stefan Heller, Ph.D., who has served on Januxs Board since 2018, has resigned.
  • "Id also like to welcome Winston to Januxs Board.
  • "I am excited to join Januxs Board to help advance the company's world-class research and emerging pipeline of tumor-activated therapeutics," said Mr. Kung.

Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO

Retrieved on: 
Wednesday, September 21, 2022

Anne Phillips, MD, FRCPC joins Carmots Board and Heather Turner, J.D., joins as Chief Operating Officer.

Key Points: 
  • Anne Phillips, MD, FRCPC joins Carmots Board and Heather Turner, J.D., joins as Chief Operating Officer.
  • We are delighted to welcome Anne Phillips to our Board, said Stig Hansen, PhD, Carmots co-founder and Chief Executive Officer.
  • "I'm also delighted to have Heather Turner join Carmot as COO and member of our executive leadership team, said Stig Hansen.
  • About Carmot Therapeutics, Inc. Carmot Therapeutics (Carmot) is focused on the discovery and development of disease-modifying therapies for patients living with metabolic diseases and cancer.

ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors

Retrieved on: 
Tuesday, September 20, 2022

ImmunoScapes differentiated Deep Immunomics platform utilizes the companys proprietary combinatorial barcoding technology to enable the discovery and in-depth characterization of rare cancer-specific T-cells at high resolution.

Key Points: 
  • ImmunoScapes differentiated Deep Immunomics platform utilizes the companys proprietary combinatorial barcoding technology to enable the discovery and in-depth characterization of rare cancer-specific T-cells at high resolution.
  • ImmunoScape has extensively validated its computational platform using virus-specific T-cells and is applying the same methods to build an extensive portfolio of cancer-specific TCRs.
  • With research laboratories in both San Diego and Singapore, ImmunoScape is one of the global pioneers of TCR discovery.
  • ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.

Merck Joins Accumulus Synergy as a Sponsor to Transform the Global Drug Regulatory Submission Process

Retrieved on: 
Tuesday, September 20, 2022

"As Accumulus Synergy continues the global journey to drive transformation towards a digital world, I am extremely pleased to have Merck join our mission.

Key Points: 
  • "As Accumulus Synergy continues the global journey to drive transformation towards a digital world, I am extremely pleased to have Merck join our mission.
  • Together, we will leverage cloud technology to improve information exchange with and among health authorities in an effort to reduce drug lag for patients around the world, said Frank Nogueira, Accumulus Synergy CEO.
  • Merck is a pioneer in developing novel medicines and vaccines and providing access to them around the world.
  • Accumulus Synergy sponsors include: Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Lilly, Merck, Pfizer, Roche, Sanofi, and Takeda.